RU2017106292A3 - - Google Patents

Download PDF

Info

Publication number
RU2017106292A3
RU2017106292A3 RU2017106292A RU2017106292A RU2017106292A3 RU 2017106292 A3 RU2017106292 A3 RU 2017106292A3 RU 2017106292 A RU2017106292 A RU 2017106292A RU 2017106292 A RU2017106292 A RU 2017106292A RU 2017106292 A3 RU2017106292 A3 RU 2017106292A3
Authority
RU
Russia
Application number
RU2017106292A
Other versions
RU2750219C2 (ru
RU2017106292A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017106292A publication Critical patent/RU2017106292A/ru
Publication of RU2017106292A3 publication Critical patent/RU2017106292A3/ru
Application granted granted Critical
Publication of RU2750219C2 publication Critical patent/RU2750219C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
RU2017106292A 2010-08-02 2011-08-02 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены RU2750219C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36990910P 2010-08-02 2010-08-02
US61/369,909 2010-08-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013109068A Division RU2612903C2 (ru) 2010-08-02 2011-08-02 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021117618A Division RU2021117618A (ru) 2021-06-17 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены

Publications (3)

Publication Number Publication Date
RU2017106292A RU2017106292A (ru) 2019-01-21
RU2017106292A3 true RU2017106292A3 (ru) 2020-12-10
RU2750219C2 RU2750219C2 (ru) 2021-06-24

Family

ID=44543797

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017106292A RU2750219C2 (ru) 2010-08-02 2011-08-02 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
RU2013109068A RU2612903C2 (ru) 2010-08-02 2011-08-02 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013109068A RU2612903C2 (ru) 2010-08-02 2011-08-02 Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены

Country Status (27)

Country Link
US (7) US9516868B2 (ru)
EP (3) EP2601298B1 (ru)
JP (6) JP6146913B2 (ru)
KR (4) KR102434557B1 (ru)
CN (3) CN105753979B (ru)
AU (1) AU2011285919C1 (ru)
BR (1) BR112013002695B1 (ru)
CA (1) CA2807282A1 (ru)
CY (1) CY1118562T1 (ru)
DK (1) DK2601298T3 (ru)
ES (1) ES2612459T3 (ru)
HK (2) HK1181810A1 (ru)
HR (1) HRP20170322T1 (ru)
HU (1) HUE031903T2 (ru)
IL (3) IL224523B (ru)
LT (1) LT2601298T (ru)
MX (5) MX345251B (ru)
MY (1) MY172618A (ru)
NZ (2) NZ707327A (ru)
PL (1) PL2601298T3 (ru)
PT (1) PT2601298T (ru)
RS (1) RS55495B1 (ru)
RU (2) RU2750219C2 (ru)
SG (3) SG10201912639SA (ru)
SI (1) SI2601298T1 (ru)
SM (1) SMT201700023B (ru)
WO (1) WO2012018764A1 (ru)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
EP3095871B1 (en) 2010-02-08 2019-04-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
ES2906462T3 (es) 2011-10-17 2022-04-18 Regeneron Pharma Ratones de cadena pesada de inmunoglobulina restringida
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR101924805B1 (ko) 2011-12-20 2018-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
DK3597038T3 (da) * 2012-02-01 2021-06-28 Regeneron Pharma Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner
EP3121194A1 (en) 2012-03-14 2017-01-25 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in fusion proteins
CA2867231C (en) 2012-03-14 2021-10-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in proteins
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR102381716B1 (ko) 2012-06-12 2022-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
WO2014130690A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
WO2014160202A1 (en) * 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2921412A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
FR3011249A1 (ru) * 2013-10-01 2015-04-03 Kymab Ltd
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
CN114478801A (zh) 2016-01-25 2022-05-13 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
CN116458475A (zh) 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
CR20230163A (es) 2016-12-07 2023-07-06 Genentech Inc ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
SG11201906540WA (en) * 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
US20190209702A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
TW202003564A (zh) 2018-03-24 2020-01-16 美商再生元醫藥公司 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
TWI829679B (zh) 2018-03-26 2024-01-21 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
KR102617284B1 (ko) 2018-06-14 2023-12-27 리제너론 파마슈티칼스 인코포레이티드 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146313A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
CA3179154A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
JP2023534437A (ja) 2020-07-13 2023-08-09 リジェネロン ファーマシューティカルズ,インク. タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用
AU2021342159A1 (en) 2020-09-11 2023-03-02 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
US20220096648A1 (en) 2020-09-14 2022-03-31 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP2024501286A (ja) 2020-12-23 2024-01-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
WO2023137026A1 (en) 2022-01-12 2023-07-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5075181A (en) 1989-05-05 1991-12-24 Kennametal Inc. High hardness/high compressive stress multilayer coated tool
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0491057B1 (en) 1990-07-10 1998-12-30 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2835787B2 (ja) 1991-03-22 1998-12-14 キヤノン株式会社 強誘電性液晶素子
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5150584A (en) 1991-09-26 1992-09-29 General Motors Corporation Method and apparatus for detecting low refrigerant charge
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994012215A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
DE4309308C1 (de) 1993-03-23 1994-04-14 Siemens Nixdorf Inf Syst Belüftungssystem für Schränke mit stark wärmeerzeugenden elektronischen Funktionseinheiten
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
CA2250830A1 (en) 1996-06-26 1997-12-31 Binhai Zheng Chromosomal rearrangement by insertion of two recombination substrates
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
WO2000073323A2 (en) 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
JP2005510253A (ja) * 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトIgλ軽鎖遺伝子を保有するトランスジェニック動物
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2003081993A2 (en) 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
FI117110B (fi) 2002-07-05 2006-06-15 Outokumpu Oy Anodin syöttö sulatusreaktoriin
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
AU2004257292A1 (en) 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1864998B2 (en) * 2004-07-22 2022-06-22 Erasmus University Medical Center Rotterdam Binding molecules
CA2827654C (en) 2004-10-19 2019-04-02 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
CA2584814A1 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in non-human transgenic animals
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP5184374B2 (ja) 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
PL2064325T3 (pl) 2006-09-01 2012-05-31 Therapeutic Human Polyclonals Inc Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2152880B1 (en) 2007-06-01 2011-08-31 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン,エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
CA2697448C (en) 2007-08-30 2019-06-11 The Burnet Institute Dendritic cell marker and uses thereof
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2271758B1 (en) 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
CN112680475A (zh) 2008-12-18 2021-04-20 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
MX2011010169A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-1/anti-c-met.
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CN101620635A (zh) * 2009-08-07 2010-01-06 中兴通讯股份有限公司 页面数据获取方法及服务器、页面更新方法及服务器
PT2954779T (pt) 2009-12-10 2019-05-29 Regeneron Pharma Ratinhos que produzem anticorpos de cadeia pesada
EP3095871B1 (en) 2010-02-08 2019-04-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CN105695415A (zh) * 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
DK2905338T3 (da) 2010-06-22 2017-11-06 Regeneron Pharma Transgene mus med et modificeret endogent lambda immunglobulin-locus
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
ES2758974T5 (es) 2011-02-25 2023-06-08 Regeneron Pharma Ratones ADAM6
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
US20120310284A1 (en) 2011-06-03 2012-12-06 Royal Oak Industries Polyaxial pedicle screw
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
ES2906462T3 (es) 2011-10-17 2022-04-18 Regeneron Pharma Ratones de cadena pesada de inmunoglobulina restringida
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR101924805B1 (ko) 2011-12-20 2018-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
DK3597038T3 (da) 2012-02-01 2021-06-28 Regeneron Pharma Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
LT3456831T (lt) 2013-04-16 2021-09-10 Regeneron Pharmaceuticals, Inc. Tikslinis žiurkės genomo modifikavimas
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen

Also Published As

Publication number Publication date
JP2013535213A (ja) 2013-09-12
HK1181810A1 (zh) 2013-11-15
US20120096572A1 (en) 2012-04-19
JP7110257B2 (ja) 2022-08-01
ES2612459T3 (es) 2017-05-17
PL2601298T3 (pl) 2017-03-31
BR112013002695B1 (pt) 2023-01-24
KR20130100277A (ko) 2013-09-10
US9686970B2 (en) 2017-06-27
WO2012018764A1 (en) 2012-02-09
MX350591B (es) 2017-09-11
SG187673A1 (en) 2013-03-28
SG10201504971QA (en) 2015-07-30
KR20200116547A (ko) 2020-10-12
HUE031903T2 (en) 2017-08-28
JP2020078328A (ja) 2020-05-28
MX2018014787A (es) 2023-02-14
RS55495B1 (sr) 2017-04-28
SI2601298T1 (sl) 2017-03-31
KR102434557B1 (ko) 2022-08-23
MX2023001793A (es) 2023-03-10
US20220177606A1 (en) 2022-06-09
NZ740900A (en) 2023-11-24
EP2601298B1 (en) 2016-11-30
US10954310B2 (en) 2021-03-23
EP2601298A1 (en) 2013-06-12
HK1217511A1 (zh) 2017-01-13
MY172618A (en) 2019-12-06
US9516868B2 (en) 2016-12-13
JP2016054746A (ja) 2016-04-21
CN105753979B (zh) 2021-05-07
SG10201912639SA (en) 2020-02-27
US20140130193A1 (en) 2014-05-08
SMT201700023B (it) 2017-03-08
RU2750219C2 (ru) 2021-06-24
AU2011285919A1 (en) 2013-02-28
US20140130194A1 (en) 2014-05-08
US20170223939A1 (en) 2017-08-10
KR20210118972A (ko) 2021-10-01
IL224523B (en) 2018-04-30
IL258338A (en) 2018-05-31
IL258338B (en) 2020-01-30
US20210163628A1 (en) 2021-06-03
JP2019047805A (ja) 2019-03-28
MX363084B (es) 2019-03-07
HRP20170322T1 (hr) 2017-04-21
CY1118562T1 (el) 2017-07-12
KR102163138B1 (ko) 2020-10-08
LT2601298T (lt) 2017-03-10
NZ606824A (en) 2015-05-29
KR102008655B1 (ko) 2019-08-08
RU2612903C2 (ru) 2017-03-13
AU2011285919B2 (en) 2015-04-30
PT2601298T (pt) 2017-01-09
JP6759303B2 (ja) 2020-09-23
NZ707327A (en) 2017-01-27
BR112013002695A2 (pt) 2017-03-01
NZ724003A (en) 2021-03-26
MX2013001360A (es) 2013-06-28
MX345251B (es) 2017-01-23
US20170226231A1 (en) 2017-08-10
EP2947151A1 (en) 2015-11-25
RU2013109068A (ru) 2014-09-10
IL271804A (en) 2020-02-27
DK2601298T3 (en) 2017-02-27
JP7078400B2 (ja) 2022-05-31
CA2807282A1 (en) 2012-02-09
JP2018046872A (ja) 2018-03-29
EP3960865A1 (en) 2022-03-02
CN103154255A (zh) 2013-06-12
JP2021119792A (ja) 2021-08-19
CN103154255B (zh) 2016-04-06
AU2011285919C1 (en) 2015-09-17
KR102306967B1 (ko) 2021-10-01
CN113150121A (zh) 2021-07-23
RU2017106292A (ru) 2019-01-21
JP6146913B2 (ja) 2017-06-14
KR20190095511A (ko) 2019-08-14
CN105753979A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
BR112013013385A2 (ru)
BR112013008959A2 (ru)
RU2017106292A3 (ru)
BR112012031500A2 (ru)
BR112012029986A2 (ru)
BR112012028408A2 (ru)
BR112012026492A2 (ru)
BR112012019354A2 (ru)
BR112012002126A2 (ru)
BR112012026946A2 (ru)
BR112012017960A2 (ru)
BR112013006400A2 (ru)
BR112012031826A2 (ru)
BR112012025577A2 (ru)
BR112012023249A2 (ru)
BR112012016456A2 (ru)
BR112012018256A2 (ru)
BR112012027945A2 (ru)
BR112012024872A2 (ru)
BR112012023265A2 (ru)
BR112013010949A2 (ru)
BR112012022788A2 (ru)
BR112013012726A2 (ru)
BR112013003284A2 (ru)
BR112013002646A2 (ru)